Literature DB >> 17545795

Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.

Nila Bhana1.   

Abstract

(1) Neutropenia is a frequent complication of chemotherapy associated with life-threatening infections, hospitalisation, and chemotherapy dose reductions and delays.(2) Primary prophylaxis with granulocyte colony-stimulating factors has been shown to reduce the incidence and duration of neutropenia, febrile neutropenia, infections, hospitalisation and antibiotic use.(3) Recent randomised clinical trials of filgrastim, lenograstim and pegfilgrastim showed variable results across patient groups at different risks of febrile neutropenia.(4) Pegfilgrastim is at least as effective as filgrastim in the prophylaxis of chemotherapy-induced neutropenia and has improved pharmacokinetics requiring reduced administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545795     DOI: 10.1097/01.cco.0000275309.58868.11

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  9 in total

1.  Racial Differences in Accepting Pegfilgrastim Onpro Kit (On-Body Injector) Use Among Cancer Patients.

Authors:  M W Saif; D W Hackenyos; M H Smith; P Healey; V Relias; K Wasif
Journal:  Clin Oncol (Las Vegas)       Date:  2019-02-25

2.  Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.

Authors:  Yanli Li; Zandra Klippel; Xiaolong Shih; Maureen Reiner; Hong Wang; John H Page
Journal:  Support Care Cancer       Date:  2016-06-08       Impact factor: 3.603

3.  G-CSF-activated STAT3 enhances production of the chemokine MIP-2 in bone marrow neutrophils.

Authors:  Hoainam T Nguyen-Jackson; Haiyan S Li; Huiyuan Zhang; Erika Ohashi; Stephanie S Watowich
Journal:  J Leukoc Biol       Date:  2012-09-27       Impact factor: 4.962

4.  Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.

Authors:  Elizabeth Fox; Brigitte C Widemann; Douglas S Hawkins; Nalini Jayaprakash; Ramzi Dagher; Alberta A Aikin; Donna Bernstein; Lauren Long; Crystal Mackall; Lee Helman; Seth M Steinberg; Frank M Balis
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

Review 5.  Homeostatic regulation of blood neutrophil counts.

Authors:  Sibylle von Vietinghoff; Klaus Ley
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

6.  Safety and Efficacy of Same-Day Administration of Pegfilgrastim in Patients Receiving Chemotherapy for Gastrointestinal Malignancies.

Authors:  Robert M Matera; Valerie Relias; Muhammad Wasif Saif
Journal:  Cancer Med J       Date:  2020-05-18

7.  Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.

Authors:  Hans L Tillmann; Keyur Patel; John G McHutchison
Journal:  Curr Gastroenterol Rep       Date:  2009-02

8.  First Analysis of Same-day Pegfilgrastim Use with Concurrent Capecitabine-based Regimens in Patients with Gastrointestinal Malignancies.

Authors:  Muhammad Wasif Saif; Nausheen Hakim; Jeffrey Chi; Hasan Rehman; Shreya Prasad Goyal; Coral Olazagasti; Patnita Forde Sheperd; Jyothi Jose
Journal:  Cancer Med J       Date:  2020-12-30

9.  Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.

Authors:  Yanli Li; Zandra Klippel; Xiaolong Shih; Hong Wang; Maureen Reiner; John H Page
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-17       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.